• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of pharmacy practice >Possible Oxcarbazepine Inductive Effects on Aripiprazole Metabolism: A Case Report
【24h】

Possible Oxcarbazepine Inductive Effects on Aripiprazole Metabolism: A Case Report

机译：可能对阿里希哌唑新陈代谢的可能性胃癌感应作用：案例报告

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Oxcarbazepine is a cytochrome P450 (CYP) 3A4 inducer, which is structurally similar to carbamazepine. Although lacking Food and Drug Administration approval, oxcarbazepine is sometimes prescribed to treat aggressive behavior in youth with autism spectrum disorder (ASD). These youths may also be taking second-generation antipsychotics, some of which are substrates of the CYP3A4 metabolic pathway. The combination of these medications may result in decreased serum antipsychotic concentrations, potentially reducing effectiveness. A limited number of reports are available which discuss reduced atypical antipsychotic concentrations secondary to oxcarbazepine CYP3A4 induction. We report a young boy taking oxcarbazepine (1200 mg/d) who presented with an unexpectedly low serum aripiprazole concentration. Utilizing therapeutic drug monitoring, pharmacogenetic testing, and a tool to evaluate drug-drug interactions, we estimate that oxcarbazepine possibly reduced his serum aripiprazole concentration by 68%. Our report is important, as it is the first to describe a drug-drug interaction between oxcarbazepine and aripiprazole. This report should encourage the completion of in vitro and clinical studies and the publication of case reports describing the possible inductive effects of oxcarbazepine on atypical antipsychotics (including cariprazine, lurasidone, quetiapine, aripiprazole, brexpiprazole, iloperidone, and risperidone) mediated by induction of the CYP3A4 metabolic pathway.
机译：Oxcarbazepine是一种细胞色素P450（CYP）3A4诱导剂，其在结构上类似于卡巴马胺。虽然缺乏食物和药物管理局的批准，但有时有有时开的Oxcarbazepine以治疗青少年的激进行为（ASD）。这些青少年也可能采用第二代抗精神病药，其中一些是CYP3A4代谢途径的底物。这些药物的组合可能导致血清抗精神病药浓度降低，可能降低有效性。有有限数量的报告，讨论氧毒脂虫CYP3A4诱导的减少的非典型抗精神病药浓度。我们举报了一个小男孩服用胃巴西（1200 mg / d），他出乎意料地呈现出意外的低血脂唑浓度。利用治疗药物监测，药物发生检测和评估药物 - 药物相互作用的工具，我们估计氧泌虫小巴可能将他的血清阿里普哌唑浓度降低68％。我们的报告很重要，因为它是第一个描述牛毒素和阿里希哌唑之间的药物 - 药物相互作用。本报告应鼓励在体外和临床研究完成，并出版案例报告，描述了通过诱导诱导的氧碱对非典型抗精神病药物（包括甲尿嘧啶，LURASIDONE，喹啉，伊硫代唑唑，伊替唑酮和锂哌唑，伊哌啶酮和Risperidone）的出版物CYP3A4代谢途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号